Zidovudine
- Generic Name
- Zidovudine
- Brand Names
- Combivir, Retrovir, Trizivir
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13N5O4
- CAS Number
- 30516-87-1
- Unique Ingredient Identifier
- 4B9XT59T7S
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
- Indication
Used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Perinatal HIV transmission
- Associated Therapies
- -
A Study of Azidothymidine Plus Methadone in Patients With AIDS and AIDS Related Complex (ARC)
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-14
- Target Recruit Count
- 18
- Registration Number
- NCT00001008
- Locations
- 🇺🇸
Montefiore Med Ctr / Bronx Municipal Hosp, Bronx, New York, United States
(Ro 24-2027) A Randomized, Double-Blind, Comparative Study of Dideoxycytidine (ddC) Versus Zidovudine (AZT) in Patients With AIDS or Advanced ARC
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-14
- Target Recruit Count
- 600
- Registration Number
- NCT00000679
- Locations
- 🇺🇸
Graduate Hosp, Philadelphia, Pennsylvania, United States
🇺🇸New England Med Ctr, Boston, Massachusetts, United States
🇺🇸Ctr for Special Immunology, Fort Lauderdale, Florida, United States
Comparison of ddI Versus Zidovudine in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-14
- Target Recruit Count
- 1500
- Registration Number
- NCT00000979
- Locations
- 🇺🇸
Whitman - Walker Clinic, Washington, District of Columbia, United States
🇺🇸Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States
🇺🇸Med Ctr of Central Massachusetts, Worcester, Massachusetts, United States
Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-02
- Target Recruit Count
- 288
- Registration Number
- NCT00001119
- Locations
- 🇺🇸
Seattle HIVNET, Seattle, Washington, United States
🇺🇸Univ of Washington, Seattle, Washington, United States
🇺🇸Univ of Minnesota, Minneapolis, Minnesota, United States
A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-02
- Target Recruit Count
- 42
- Registration Number
- NCT00000897
- Locations
- 🇺🇸
Children's Hosp at Albany Med Ctr, Albany, New York, United States
🇺🇸SUNY / Erie County Med Ctr at Buffalo, Buffalo, New York, United States
🇺🇸Univ of Washington, Seattle, Washington, United States
The Effects of Zidovudine on the Blood of HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-01
- Target Recruit Count
- 20
- Registration Number
- NCT00000965
- Locations
- 🇺🇸
Univ of Cincinnati, Cincinnati, Ohio, United States
A Comparison of Zidovudine Plus Lamivudine Versus ddI Used Alone or in Combination With Zidovudine in HIV-1 Infected Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-02
- Target Recruit Count
- 740
- Registration Number
- NCT00001066
- Locations
- 🇺🇸
HRS Palm Beach County Public Health Unit, West Palm Beach, Florida, United States
🇺🇸Children's Hosp of Washington DC, Washington, District of Columbia, United States
🇺🇸Howard Univ Hosp, Washington, District of Columbia, United States
Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 300
- Registration Number
- NCT00001040
- Locations
- 🇺🇸
Stanford Univ Med Ctr, Stanford, California, United States
🇺🇸Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
🇺🇸Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States
A Study of Nevirapine Used Alone or in Combination With AZT in HIV-1-Infected Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-01
- Target Recruit Count
- 35
- Registration Number
- NCT00001111
- Locations
- 🇺🇸
UCLA Med Ctr / Pediatrics, Los Angeles, California, United States
🇺🇸Univ of Miami (Pediatric), Miami, Florida, United States
🇺🇸Univ of Massachusetts Med Ctr / Biotech II, Worcester, Massachusetts, United States
A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 18
- Registration Number
- NCT00000694
- Locations
- 🇺🇸
Mem Sloan - Kettering Cancer Ctr, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.